30 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
creation, which include:
◦Closing R&D facilities in St. Louis, Missouri and Portland, Oregon in 2024. Research activities will continue at the Company’s … of sotrovimab.
Research and Development Expenses (R&D): R&D expenses for the fourth quarter of 2023 were $111.9 million, which included severance
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
on the sales of sotrovimab.
Research and Development Expenses (R&D): R&D expenses for the third quarter of 2023 were $148.3 million, which included $15.8 … -back the R&D credit to 2022.
Net (Loss) Income: Net loss attributable to Vir for the third quarter of 2023 was $(163.4) million, or $(1.22) per share
8-K
EX-99.1
yyg5anlp20xz sbz1quu
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
zt1axzefqg iv
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
8-K
EX-99.1
7a61ydz jl
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
mm6d92 vsw
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
zutx8h7xwrs
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm
8-K
EX-99.2
uy2yd1x7k2vivdtkv
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm
8-K
EX-99.1
fhmqf1zc
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.2
lq5 o4hp4qg7vx
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.1
o10fwb8v
13 Apr 21
Other Events
4:06pm